A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients

Trial Profile

A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2016

At a glance

  • Drugs Rabeprazole (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Registrational; Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 28 Oct 2016 According to an Eisai media release, the company has submitted an application for rabeprazole in Japan seeking approval for an additional dosage administration of 10 mg twice-daily for the treatment of PPI resistant reflux esophagitis.
    • 29 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 11 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top